US Primary Osteoarthritis Market Summary

As per Market Research Future analysis, the US Primary Osteoarthritis Market size was estimated at 1455.3 USD Million in 2024. The US primary osteoarthritis market is projected to grow from 1574.49 USD Million in 2025 to 3458.3 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.1% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The US primary osteoarthritis market is experiencing notable growth driven by demographic shifts and advancements in treatment options.

The rising prevalence of primary osteoarthritis is particularly evident among the aging population, which constitutes the largest segment of affected individuals.
Advancements in treatment options are enhancing patient outcomes, contributing to a more engaged patient population.
Increased patient awareness and engagement are fostering a proactive approach to managing osteoarthritis, especially in the fastest-growing segment of younger adults.
Key market drivers include growing healthcare expenditure and rising obesity rates, which are significantly impacting the demand for osteoarthritis management solutions.

Market Size & Forecast

2024 Market Size	1455.3 (USD Million)
2035 Market Size	3458.3 (USD Million)
CAGR (2025 - 2035)	8.19%

Major Players

Pfizer Inc (US), Johnson & Johnson (US), Boehringer Ingelheim (DE), Novartis AG (CH), AbbVie Inc (US), Amgen Inc (US), Sanofi (FR), GlaxoSmithKline plc (GB), Eli Lilly and Company (US)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

US Primary Osteoarthritis Market Trends

The US Primary Osteoarthritis Market is currently experiencing notable shifts driven by various factors. The increasing prevalence of this degenerative joint disease among the aging population appears to be a significant contributor to market growth. As individuals age, the likelihood of developing osteoarthritis rises, leading to a greater demand for effective treatment options. Furthermore, advancements in medical technology and pharmaceuticals are likely enhancing the availability of innovative therapies, which may improve patient outcomes and quality of life. This evolving landscape suggests that stakeholders in the primary osteoarthritis market must remain vigilant and adaptable to changing patient needs and treatment modalities. In addition, the rising awareness of osteoarthritis and its impact on daily living seems to be influencing patient engagement and healthcare provider practices. Educational initiatives aimed at both patients and healthcare professionals are likely fostering a better understanding of the condition, which may lead to earlier diagnosis and intervention. As a result, the primary osteoarthritis market is poised for continued growth, driven by a combination of demographic trends, technological advancements, and increased awareness of the disease's implications.

Rising Prevalence Among Aging Population

The primary osteoarthritis market is witnessing an increase in cases due to the aging demographic. As the population ages, the incidence of osteoarthritis is expected to rise, leading to a higher demand for treatment options. This trend indicates a need for healthcare systems to adapt and provide adequate resources for managing this condition.

Advancements in Treatment Options

Innovations in medical technology and pharmaceuticals are shaping the primary osteoarthritis market. New therapies and treatment modalities are emerging, potentially improving patient outcomes. These advancements may also encourage healthcare providers to explore alternative approaches to managing osteoarthritis.

Increased Patient Awareness and Engagement

There is a growing emphasis on educating patients about osteoarthritis and its management. Increased awareness is likely leading to more proactive patient engagement in their treatment plans. This trend may result in earlier diagnosis and intervention, ultimately benefiting the primary osteoarthritis market.

US Primary Osteoarthritis Market Drivers

Rising Obesity Rates

The prevalence of obesity in the US is a critical driver impacting the primary osteoarthritis market. Data suggests that approximately 42.4% of adults in the US are classified as obese, a condition that significantly increases the risk of developing osteoarthritis due to the added stress on weight-bearing joints. This correlation indicates a growing patient population that may require treatment for osteoarthritis, thereby expanding the market. As healthcare professionals increasingly recognize the link between obesity and joint health, there is a push for integrated treatment approaches that address both weight management and osteoarthritis. This trend may lead to a rise in demand for therapeutic interventions, further propelling the primary osteoarthritis market.

Growing Healthcare Expenditure

The primary osteoarthritis market is experiencing a notable increase in healthcare expenditure in the US. As the population ages, healthcare spending is projected to rise significantly, with estimates indicating that it could reach over $4 trillion by 2025. This surge in spending is likely to enhance access to various treatment options for osteoarthritis, including medications, physical therapy, and surgical interventions. Furthermore, the increased allocation of funds towards research and development may lead to innovative therapies, thereby expanding the primary osteoarthritis market. The focus on improving patient outcomes and quality of life is driving healthcare providers to invest more in osteoarthritis management, which could potentially lead to a more robust market landscape.

Expansion of Telehealth Services

The rise of telehealth services is significantly influencing the primary osteoarthritis market. With the increasing adoption of digital health technologies, patients now have greater access to healthcare professionals from the comfort of their homes. This trend is particularly beneficial for individuals with mobility issues or those living in remote areas. Telehealth consultations can facilitate timely assessments and management of osteoarthritis, ensuring that patients receive appropriate care without the barriers of traditional healthcare settings. As telehealth continues to expand, it is likely to enhance patient engagement and adherence to treatment plans, thereby positively impacting the primary osteoarthritis market.

Increased Focus on Preventive Care

The primary osteoarthritis market is witnessing a shift towards preventive care strategies. Healthcare providers are increasingly emphasizing the importance of early intervention and lifestyle modifications to mitigate the risk of developing osteoarthritis. This proactive approach includes promoting physical activity, weight management, and nutritional counseling. As awareness of the benefits of preventive care grows, more individuals are likely to seek guidance on maintaining joint health, which could lead to an increase in demand for preventive services and products. This trend may not only enhance patient outcomes but also contribute to the overall growth of the primary osteoarthritis market as healthcare systems adapt to prioritize prevention.

Technological Innovations in Diagnostics

Technological advancements in diagnostic tools are transforming the primary osteoarthritis market. Innovations such as advanced imaging techniques, including MRI and ultrasound, allow for earlier and more accurate diagnosis of osteoarthritis. These developments enable healthcare providers to tailor treatment plans more effectively, potentially improving patient outcomes. The integration of artificial intelligence in diagnostic processes is also emerging, which may enhance the efficiency and accuracy of identifying osteoarthritis. As these technologies become more accessible, they are likely to increase the number of diagnosed cases, thereby expanding the primary osteoarthritis market. The emphasis on precision medicine is expected to drive further investment in diagnostic innovations.

Market Segment Insights

By Type: Knee Osteoarthritis (Largest) vs. Hand Osteoarthritis (Fastest-Growing)

In the US primary osteoarthritis market, knee osteoarthritis dominates with the largest market share due to its prevalence and significant impact on mobility. Other segments like hip osteoarthritis and spinal osteoarthritis also hold noteworthy shares but do not surpass the dominance of knee osteoarthritis. Hand osteoarthritis, while smaller in terms of overall share, is catching up as awareness and diagnosis improve. The growth trends indicate a rising incidence of osteoarthritis across various demographics, particularly among the aging population. Knee osteoarthritis remains the focal point of treatment advancements, while hand osteoarthritis is witnessing rapid innovations in therapeutics, making it the fastest-growing segment. Enhanced awareness and healthcare investments are significant drivers pushing these segments forward.

Knee Osteoarthritis (Dominant) vs. Hand Osteoarthritis (Emerging)

Knee osteoarthritis is characterized by its high prevalence, making it a major focus in the US primary osteoarthritis market. This segment is driven by aging populations and lifestyle factors leading to increased joint wear. Improvements in surgical and non-surgical treatments contribute to its dominant position, with ongoing research into new therapeutic options. In contrast, hand osteoarthritis, while emerging, is gaining traction due to advancements in diagnosis and treatment options that cater specifically to this type. The rising emphasis on quality of life and functional improvement for sufferers makes hand osteoarthritis a fast-growing segment, with increasing investments in innovative therapies and patient education.

By Diagnosis: Imaging (Largest) vs. Joint Fluid Analysis (Fastest-Growing)

In the US primary osteoarthritis market, imaging techniques dominate the diagnosis segment, holding the largest share due to their advanced capabilities in visualizing joint conditions. Joint fluid analysis follows, while other diagnostic methods, although present, play a minor role in comparison. The preference for imaging is driven by its ability to provide comprehensive insights into joint degeneration and other related issues. Growth trends within the diagnosis segment reveal a significant uptick in joint fluid analysis, marked as the fastest-growing method. Increased awareness about early diagnosis and technological advancements in diagnostic tools are propelling this growth. Healthcare providers are increasingly adopting these methods, and enhanced accuracy in diagnosing the condition is becoming a priority, which further drives market expansion.

Imaging (Dominant) vs. Joint Fluid Analysis (Emerging)

Imaging methods, including X-rays and MRI, are the dominant diagnostic tools in the segment, offering accurate images of joint structures and helping in assessing the severity of osteoarthritis. They play a critical role in informing treatment decisions. Conversely, joint fluid analysis is an emerging method that seeks to provide insights into inflammation and other biochemical markers in joint fluid. This method is gaining traction due to its potential for early diagnosis and personalized treatment approaches, indicating a shift towards more nuanced and effective diagnostic strategies within the US primary osteoarthritis market.

By Treatment: Medication (Largest) vs. Therapies (Fastest-Growing)

In the US primary osteoarthritis market, the treatment segment comprises various approaches such as medication, therapies, surgery, and others. Medication holds a significant market share, being the largest contributor in terms of utilization and revenue, while therapies are emerging as the fastest-growing part of this segment. The distribution showcases a well-established preference for medications as primary treatments, with increasing engagement towards alternative therapies that provide additional benefits to patients during the management of osteoarthritis. Growth trends in this segment are influenced by several factors including an aging population, rising awareness of osteoarthritis management, and a shift towards non-invasive treatments. The demand for personalized therapies, such as physical therapy and biologic agents, is increasing, indicating a change in patient preferences. Innovations in drug development and therapy methodologies drive the expansion of both medication and therapies, revealing a dynamic landscape responsive to patient needs and market trends.

Medication (Dominant) vs. Therapies (Emerging)

Medication serves as the dominant force in the treatment segment of the US primary osteoarthritis market, encompassing various classes such as analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. Its established presence is attributed to the immediate relief it provides for symptoms, making it the first line of treatment for many patients. In contrast, therapies are identified as the emerging segment, gaining traction through their holistic approach, including physical and occupational therapy, which are vital for improving mobility and functionality. Both segments coalesce within the treatment paradigm, yet their methods differ significantly; while medication targets pain and inflammation directly, therapies aim to enhance long-term joint function and quality of life, leading to an integrated approach in the management of osteoarthritis.

By End-user: Hospitals & Clinics (Largest) vs. Medical Institutes (Fastest-Growing)

In the US primary osteoarthritis market, hospitals and clinics represent the largest share of the end-user segment, providing a wide array of treatment options and advanced care facilities tailored for osteoarthritis patients. This segment benefits from established trust and extensive infrastructure, enabling comprehensive patient management and procedural capabilities. Conversely, medical institutes, although smaller in share, are emerging rapidly due to their focus on innovative treatment methodologies and pioneering research initiatives aimed at optimizing osteoarthritis care. As awareness of osteoarthritis increases and the demand for specialized care grows, these institutions are capturing a significant portion of the market. Growth trends in the end-user segment are driven by an increasing patient population and advancements in treatment options, with hospitals and clinics leading the way due to their robust service offerings. Medical institutes are being propelled by their commitment to research and development, which attracts both patients and funding. This dual approach is likely to foster collaborations that can enhance patient care and develop novel therapeutic strategies, thereby supporting the sustained growth of both segments in the coming years.

Hospitals & Clinics (Dominant) vs. Medical Institutes (Emerging)

Hospitals and clinics dominate the end-user segment in the US primary osteoarthritis market, owing to their extensive networks and capacity to provide multifaceted care ranging from diagnostics to rehabilitation. Their established infrastructure facilitates timely and effective treatment, addressing the growing needs of the osteoarthritis patient population. In contrast, medical institutes represent the emerging force, focusing on cutting-edge research and specialized care approaches designed to improve treatment outcomes. These institutions are increasingly recognized for their innovative therapies and are actively engaging in clinical trials, which not only enhance their service profiles but also foster strategic partnerships aimed at advancing the understanding and treatment of osteoarthritis.

Get more detailed insights about US Primary Osteoarthritis Market

Request Free Sample

Key Players and Competitive Insights

The primary osteoarthritis market in the US is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Pfizer Inc (US), AbbVie Inc (US), and Eli Lilly and Company (US) are actively engaged in developing novel therapies and enhancing their market presence. Pfizer Inc (US) has positioned itself as a leader in the market through its commitment to research and development, particularly in biologics and disease-modifying osteoarthritis drugs (DMOADs). AbbVie Inc (US) has focused on expanding its portfolio through strategic acquisitions and collaborations, aiming to leverage its existing expertise in immunology to address osteoarthritis more effectively. Eli Lilly and Company (US) is also making strides by investing in digital health solutions that enhance patient engagement and treatment adherence, thereby shaping the competitive dynamics of the market.The business tactics employed by these companies reflect a nuanced understanding of the market's structure, which appears to be moderately fragmented. Localizing manufacturing and optimizing supply chains are critical strategies that these companies are adopting to enhance operational efficiency and reduce costs. The collective influence of these key players is significant, as they not only drive innovation but also set benchmarks for quality and efficacy in treatment options, thereby influencing the overall market dynamics.
In October Pfizer Inc (US) announced a partnership with a leading digital health company to develop a mobile application aimed at improving patient monitoring and adherence to osteoarthritis treatments. This strategic move is likely to enhance patient outcomes by providing real-time data and personalized treatment plans, thereby reinforcing Pfizer's commitment to patient-centric care. The integration of digital health solutions into traditional treatment paradigms may also serve to differentiate Pfizer in a competitive market.
In September AbbVie Inc (US) completed the acquisition of a biotech firm specializing in regenerative medicine, which is expected to bolster its capabilities in developing innovative therapies for osteoarthritis. This acquisition not only expands AbbVie's product pipeline but also positions the company to leverage cutting-edge technologies in regenerative medicine, potentially leading to breakthrough treatments that could redefine patient care in osteoarthritis.
In August Eli Lilly and Company (US) launched a new clinical trial for a novel DMOAD, which aims to slow the progression of osteoarthritis. This initiative underscores Eli Lilly's focus on innovation and its commitment to addressing unmet medical needs in the osteoarthritis space. The outcomes of this trial could significantly impact the company's market position and contribute to the broader understanding of osteoarthritis treatment efficacy.
As of November the competitive trends in the primary osteoarthritis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances research capabilities and accelerates the development of new therapies. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. Companies that can effectively harness these trends will likely secure a competitive edge in the dynamic osteoarthritis market.

Key Companies in the US Primary Osteoarthritis Market include

Industry Developments

The US Primary Osteoarthritis Market is currently witnessing significant developments. In September 2023, Eli Lilly entered into an agreement with Horizon Therapeutics to enhance its product portfolio addressing pain management related to osteoarthritis, highlighting the competitive landscape of leading pharmaceuticals in treating this condition. Additionally, Merck and Co. announced the successful results from a Phase 3 trial for its new osteoarthritis pain relief medication, which is anticipated to significantly contribute to its revenue stream post-approval.

Over the past two years, the companies have seen substantial valuation growth, with Pfizer and GlaxoSmithKline making strategic investments aimed at expanding their therapeutic options, further pushing advancements in treatments. Regulatory changes in mid-2023 also focused on market access for biologics that target osteoarthritis, which adds a layer of complexities and opportunities for firms like AbbVie and Sorrento Therapeutics. Meanwhile, there have been discussions surrounding potential mergers, including speculation around Johnson and Johnson potentially acquiring smaller biotech firms to strengthen its portfolio in osteoarthritis.

Overall, the competitive landscape is evolving rapidly, reflecting increased investment and strategic collaborations among major players in the market.

Future Outlook

US Primary Osteoarthritis Market Future Outlook

The Primary Osteoarthritis Market is projected to grow at an 8.19% CAGR from 2025 to 2035, driven by increasing aging population, rising obesity rates, and advancements in treatment options.

New opportunities lie in:

Development of telehealth platforms for remote patient monitoring and consultations. Investment in AI-driven diagnostic tools to enhance early detection and treatment. Expansion of personalized medicine approaches tailored to individual patient profiles.

By 2035, the primary osteoarthritis market is expected to achieve substantial growth and innovation.

Market Segmentation

US Primary Osteoarthritis Market Type Outlook

knee osteoarthritis
hand osteoarthritis
neck osteoarthritis
hip osteoarthritis
wrist osteoarthritis
spinal osteoarthritis
shoulder osteoarthritis
others

US Primary Osteoarthritis Market End-user Outlook

hospitals & clinics
medical institutes
research organization
others

US Primary Osteoarthritis Market Diagnosis Outlook

imaging
joint fluid analysis
others

US Primary Osteoarthritis Market Treatment Outlook

medication
therapies
surgery
others

Report Scope

MARKET SIZE 2024	1455.3(USD Million)
MARKET SIZE 2025	1574.49(USD Million)
MARKET SIZE 2035	3458.3(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.19% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	Pfizer Inc (US), Johnson & Johnson (US), Boehringer Ingelheim (DE), Novartis AG (CH), AbbVie Inc (US), Amgen Inc (US), Sanofi (FR), GlaxoSmithKline plc (GB), Eli Lilly and Company (US)
Segments Covered	Type, Diagnosis, Treatment, End-user
Key Market Opportunities	Integration of digital therapeutics and personalized medicine in the primary osteoarthritis market.
Key Market Dynamics	Rising demand for innovative therapies drives competition and regulatory scrutiny in the primary osteoarthritis market.
Countries Covered	US

FAQs

What was the overall market valuation of the US primary osteoarthritis market in 2024?

The overall market valuation was $1455.3 Million in 2024.

What is the projected market valuation for the US primary osteoarthritis market by 2035?

The projected market valuation for 2035 is $3458.3 Million.

What is the expected CAGR for the US primary osteoarthritis market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 8.19%.

Which segment had the highest valuation in the US primary osteoarthritis market in 2024?

The knee osteoarthritis segment had the highest valuation at $600.0 Million in 2024.

What are the projected valuations for the hand osteoarthritis segment by 2035?

The projected valuation for the hand osteoarthritis segment by 2035 is between $250.0 Million and $600.0 Million.

How much is expected to be spent on medication for treating primary osteoarthritis by 2035?

Spending on medication for treating primary osteoarthritis is expected to reach between $600.0 Million and $1400.0 Million by 2035.

What role do hospitals and clinics play in the US primary osteoarthritis market?

Hospitals and clinics accounted for a valuation of $600.0 Million in 2024 and are expected to remain a key end-user.

Which company is a key player in the US primary osteoarthritis market?

Pfizer Inc is one of the key players in the US primary osteoarthritis market.

What is the projected valuation for imaging as a diagnostic method by 2035?

The projected valuation for imaging as a diagnostic method by 2035 is between $500.0 Million and $1200.0 Million.

What is the expected growth trend for therapies in the US primary osteoarthritis market?

The therapies segment is projected to grow to between $400.0 Million and $900.0 Million by 2035.

Author

Author

Satyendra Maurya

Research Analyst

An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.

Co-Author

Garvit Vyas

Vice President - Operations

Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.

Get In Touch

Leave a Comment